Erkan Kiriş
Assistant Professor
      

RESEARCH AREA
Neurodegenerative Diseases

CONTACT INFORMATION

+90 (312) 210 5169
Office Z-16

METU AVESIS Profile  
PREVIOUS EXPERIENCE

Research Scientist

2009-2017

Neural Development Section (Tessarollo Laboratory), Mouse Cancer Genetics Program, National Cancer Institute at Frederick, National Institutes of Health (In collaboration with US Army Medical Research Institute of Infectious Diseases — Bavari Laboratory), Frederick, MD, USA

Postdoctoral Researcher

2008-2009

Neuroscience Research Institute, University of California, Santa Barbara, CA, USA

EDUCATION

Ph.D

2003-2008

Department of Molecular, Cell and Developmental Biology, University of California, Santa Barbara, CA, USA

M.Sc

2000-2003

Faculty of Arts and Science, Department of Biology, Mugla University, Mugla, Turkiye

B.Sc

1996-2000

Faculty of Education, Department of Biology, Selcuk University, Konya, Turkiye

RESEARCH SUMMARY

Our laboratory conducts research in the field of molecular neurobiology, utilizing mouse embryonic stem cell and patient-derived human induced pluripotent stem cell-based neuronal and glial models. Our research interests include,

  1. Modulation of neurotrophin signaling against neurodegenerative diseases,
  2. Molecular mechanisms underlying sex-specific differences in neurodegenerative diseases. More specifically, we study whether neurotrophin signaling and estrogen receptor signaling work in concert, potentially in a sex-specific manner, in neuroprotection in the context of neurodegenerative diseases, using patient-derived human induced pluripotent stem cell-based neuronal and glial model systems, and
  3. Botulinum Neurotoxin (BoNT) research and drug discovery:
    1. identification of mechanism-targeted compounds to discover novel leads that can be effective against multiple BoNT serotypes responsible for human botulism cases, using physiologically relevant motor neuron systems,
    2. elucidation of critical molecular mechanisms involved in the intoxication and/or recovery, and
    3. developing stem cell based detection technologies for these toxins.

SELECTED PUBLICATIONS

E. Sen, K.P. Kota, R.G. Panchal, S. Bavari, and E. Kiris (2021). “Screening of a Focused Ubiquitin-Proteasome Pathway Inhibitor Library Identifies Small Molecules as Novel Modulators of Botulinum Neurotoxin Type A Toxicity”. Frontiers in Pharmacology, Volume 12, 2659, doi:10.3389/fphar.2021.763950.


O.C. Begentas, D. Koc, S. Yurtogullari, M. Temel, K.C. Akcali, S. Demirkaya, and E. Kiris (2021). “Generation and characterization of human induced pluripotent stem cell line METUi001-A from a 25-year-old male patient with relapsing-remitting multiple sclerosis”. Stem Cell Research, Volume 53, 102370, doi:10.1016/j.scr.2021.102370.


E. Kiris, J. C. Burnett, J. E. Nuss, L. M. Wanner, B. D. Peyser, H. T. Du, G. Y. Gomba, K. P. Kota, R. Panchal, R. Gussio, C.D. Kane, L. Tessarollo, and S. Bavari (2015). “Src family kinase inhibitors antagonize the toxicity of multiple serotypes of Botulinum neurotoxin in human embryonic stem cell-derived motor neurons”. Neurotoxicity Research, 27:384–398, doi:10.1007/s12640-015-9526-z.


E. Kiris*, T. Wang*, S. Yanpallewar, S. Dorsey, J. Becker, S. Bavari, M.E. Palko, V. Coppola, and L. Tessarollo (2014). “TrkA in vivo function is negatively regulated by ubiquitination”. The Journal of Neuroscience, Mar 12;34(11):4090-8. doi: 10.1523/JNEUROSCI.4294-13.2014. *Equal Contribution.


E. Kiris, D. Ventimiglia, M. R. Gaylord, M.E. Sargin, A. Altinok, K. Rose, B.S. Manjunath, M. A. Jordan, L. Wilson and S. C. Feinstein (2011). “Combinatorial Tau Pseudophosphorylation: Markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts”. Journal of Biological Chemistry, 286, 14257-14270, doi: 10.1074/jbc.M111.219311.


Last Updated:
14/04/2022 - 15:22